Divi's Laboratories Limited vs GlaxoSmithKline Pharmaceuticals Limited
A side-by-side comparison of Divi's Laboratories Limited (DIVISLAB) and GlaxoSmithKline Pharmaceuticals Limited (GLAXO) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.
On the numbers, GlaxoSmithKline Pharmaceuticals Limited leads DIVISLAB vs GLAXO on 7 of 14 metrics (1 undecided). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).
- Valuation22
- Profitability04
- Growth11
- Size & financial health30
Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.
Valuation
EvenHow expensive each stock is relative to its earnings and book value. Lower usually means cheaper.
Profitability
GLAXO takes 4/4How efficiently each company turns capital and sales into profit. Higher is better.
Growth
EvenThree-year compounded growth. Faster-growing businesses can justify a higher valuation.
Size & financial health
DIVISLAB takes 3/4Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.
- + ["Company has been maintaining a healthy dividend payout of 31.0%", "Company is almost debt free."]
- − ["Stock is trading at 14.48 times its book value", "The company has delivered a poor sales growth of 8.7% over past five years."]
- + ["Company has delivered good profit growth of 23.7% CAGR over last 5 years", "Company has a good return on equity (ROE) track record: 3 Years ROE 44.1%", "Company has been maintaining a healthy dividend payout of 93.2%", "Company is almost debt free."]
- − ["Stock is trading at 19.17 times its book value", "The company has delivered a poor sales growth of 5.5% over past five years."]
This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.